KL1333
- Generic Name
- KL1333
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H12N2O2
- CAS Number
- 1800405-30-4
- Unique Ingredient Identifier
- NA2ZOL5UGM
- Associated Conditions
- -
- Associated Therapies
- -
Pharming announces public cash offer to the shareholders of Abliva AB
Pharming Group N.V. announced a recommended public cash offer to acquire Abliva AB, valuing the transaction at approximately US$66.1 million. Abliva’s lead product, KL1333, is in a pivotal clinical trial for mitochondrial DNA-driven primary mitochondrial diseases, with a positive interim analysis. The acquisition strengthens Pharming’s late-stage pipeline and aligns with its vision to become a leading global rare disease company.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath